Literature DB >> 16328667

Focal segmental glomerulosclerosis associated with mitochondrial cytopathy: report of two cases with special emphasis on podocytes.

Safak Güçer1, Beril Talim, Esin Aşan, Petek Korkusuz, Seza Ozen, Sule Unal, Serap H Kalkanoğlu, Gülsev Kale, Melda Cağlar.   

Abstract

We report two children with focal segmental glomerulosclerosis (FSGS) associated with mitochondrial cytopathy (MC). Case 1 was diagnosed as MC with the findings of ptosis, ophthalmoplegia, failure to thrive, high serum lactate and pyruvate levels, ragged red fibers in muscle biopsy and the common 4.9 kb deletion in mtDNA when she was four years old. She subsequently developed FSGS four years later. Case 2 was a four month-old girl presenting with feeding difficulty from birth, with vomiting, seizures and nystagmoid eye movements, nephrotic proteinuria and hematuria. Renal biopsy revealed FSGS. Ultrastructural study demonstrated markedly pleomorphic mitochondria in podocytes with a severe effacement of foot processes. The analyses of muscle biopsy and skin fibroblasts for respiratory chain enzymes were found to be normal, while mitochondrial DNA analysis revealed the population of a single deleted mtDNA in the heteroplasmic state. The present cases illustrate FSGS as a rare renal complication of mitochondrial disease and provide further evidence of podocytes possessing abnormal mitochondria which may cause glomerular epithelial cell damage leading to glomerulosclerosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16328667     DOI: 10.1007/s10024-005-0058-z

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  18 in total

1.  Knocking down Cabin1 induces glomerular podocyte injury.

Authors:  Yueqiang Wen; Lingling Liu; Qingdong Xu; Peilan Zhou; Huiyuan Li; Zebin Wang; Jianbo Liang
Journal:  Int Urol Nephrol       Date:  2018-01-24       Impact factor: 2.370

Review 2.  Mitochondria in Acute Kidney Injury.

Authors:  Kenneth M Ralto; Samir M Parikh
Journal:  Semin Nephrol       Date:  2016-01       Impact factor: 5.299

3.  Increasing the level of peroxisome proliferator-activated receptor γ coactivator-1α in podocytes results in collapsing glomerulopathy.

Authors:  Szu-Yuan Li; Jihwan Park; Chengxiang Qiu; Seung Hyeok Han; Matthew B Palmer; Zoltan Arany; Katalin Susztak
Journal:  JCI Insight       Date:  2017-07-20

4.  An autopsy case of chronic progressive external ophthalmoplegia with renal insufficiency.

Authors:  Takashi Yuri; Yaeko Kondo; Keiko Kohno; Yen-Chang Lei; Seika Kanematsu; Maki Kuwata; Toshiji Iwasaka; Airo Tsubura
Journal:  Med Mol Morphol       Date:  2008-12-24       Impact factor: 2.309

Review 5.  The Emerging Role of Mitochondrial Targeting in Kidney Disease.

Authors:  Alfonso Eirin; Amir Lerman; Lilach O Lerman
Journal:  Handb Exp Pharmacol       Date:  2017

6.  Renal mitochondrial cytopathies.

Authors:  Francesco Emma; Giovanni Montini; Leonardo Salviati; Carlo Dionisi-Vici
Journal:  Int J Nephrol       Date:  2011-07-27

Review 7.  Renal involvement in mitochondrial cytopathies.

Authors:  Francesco Emma; Enrico Bertini; Leonardo Salviati; Giovanni Montini
Journal:  Pediatr Nephrol       Date:  2011-06-09       Impact factor: 3.714

8.  Huaier Cream Protects against Adriamycin-Induced Nephropathy by Restoring Mitochondrial Function via PGC-1α Upregulation.

Authors:  Ruochen Che; Chunhua Zhu; Guixia Ding; Min Zhao; Mi Bai; Zhanjun Jia; Aihua Zhang; Songming Huang
Journal:  PPAR Res       Date:  2015-03-11       Impact factor: 4.964

Review 9.  The podocyte power-plant disaster and its contribution to glomerulopathy.

Authors:  Janina Müller-Deile; Mario Schiffer
Journal:  Front Endocrinol (Lausanne)       Date:  2014-12-15       Impact factor: 5.555

10.  Mitochondrial Dysfunction in Podocytes Caused by CRIF1 Deficiency Leads to Progressive Albuminuria and Glomerular Sclerosis in Mice.

Authors:  Ki Ryang Na; Jin Young Jeong; Jin Ah Shin; Yoon-Kyung Chang; Kwang-Sun Suh; Kang Wook Lee; Dae Eun Choi
Journal:  Int J Mol Sci       Date:  2021-05-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.